U.S. Records 27% Increase in Recalled Products in Q1 2026
U.S. product recall activity remained elevated in the first quarter of 2026 as companies faced increasing regulatory pressure and ongoing disruptions within global supply chains.
According to the company, the total volume of defective products recalled across five U.S. industries increased by 27% quarter-over-quarter, reaching 492 million units in Q1 2026. In contrast, the number of recall events declined by 10.5%, from 877 in Q4 2025 to 785 in Q1 2026. This data indicates that while fewer recalls were announced in total, the scale and impact of individual events have intensified.
The quarterly Product Safety and Recall Index report from Sedgwick provides a comprehensive analysis and insight into recall activity across the U.S. automotive, consumer products, food and drink, pharmaceutical, and medical device industries. The latest edition reviews recall data from January through March, along with an early look at developments in April that are shaping the product safety landscape.
Among the key findings, the consumer products sector was the only industry to report an increase in recall events, which rose by 14.5% to 142. This sector also saw a 347% increase in recalled units quarter-over-quarter.
Significant numbers of units recalled in Q1 came from several industries. The pharmaceutical sector reached a 12-year high with 218.8 million units impacted. The automotive industry reported its highest quarterly unit total since Q1 2024, with 12.2 million vehicles recalled. Additionally, USDA-regulated food recalls accounted for 37.1 million pounds of product, marking the third-highest total in over two decades.
The report further highlights recent regulatory developments that will continue to affect product safety throughout 2026. Both the USDA and Federal Trade Commission (FTC) have tightened enforcement around country-of-origin claims for U.S.-made products. The FTC is also closely monitoring auto dealerships to ensure advertised prices are transparent, preventing hidden fees for consumers. Meanwhile, the FDA has amended inspection procedures for medical devices and pharmaceutical products, indicating that companies across all industries should prepare for increased regulatory changes in the coming months.